Your browser doesn't support javascript.
loading
Efficacy of Tamsulosin, Oxybutynin, and their combination in the control of double-j stent-related lower urinary tract symptoms
Maldonado-Avila, Miguel; Garduño-Arteaga, Leopoldo; Jungfermann-Guzman, Rene; Manzanilla-Garcia, Hugo A; Rosas-Nava, Emmanuel; Procuna-Hernandez, Nestor; Vela-Mollinedo, Alejandro; Almazan-Treviño, Luis; Guzman-Esquivel, Jose.
  • Maldonado-Avila, Miguel; Hospital Geral de Mexico. Departamento de Urologia. Ciudad de Mexico. MX
  • Garduño-Arteaga, Leopoldo; Hospital Geral de Mexico. Departamento de Urologia. Ciudad de Mexico. MX
  • Jungfermann-Guzman, Rene; Hospital Geral de Mexico. Departamento de Urologia. Ciudad de Mexico. MX
  • Manzanilla-Garcia, Hugo A; Hospital Geral de Mexico. Departamento de Urologia. Ciudad de Mexico. MX
  • Rosas-Nava, Emmanuel; Hospital Geral de Mexico. Departamento de Urologia. Ciudad de Mexico. MX
  • Procuna-Hernandez, Nestor; Hospital Geral de Mexico. Departamento de Urologia. Ciudad de Mexico. MX
  • Vela-Mollinedo, Alejandro; Hospital Geral de Mexico. Departamento de Urologia. Ciudad de Mexico. MX
  • Almazan-Treviño, Luis; Hospital Geral de Mexico. Departamento de Urologia. Ciudad de Mexico. MX
  • Guzman-Esquivel, Jose; Hospital Geral de Mexico. Departamento de Urologia. Ciudad de Mexico. MX
Int. braz. j. urol ; 42(3): 487-493, tab, graf
Article in English | LILACS | ID: lil-785727
ABSTRACT
ABSTRACT Introduction and objective Indwelling double J ureteral stents are used routinely in the resolution of ureteral obstruction caused by different etiologies. Evaluation of urinary symptoms related to double-J stent, indicate that these affect 73-90% of patients. We conducted a prospective, randomized study, to evaluate the efficacy of tamsulosin, oxybutinin and combination therapy in improving the urinary symptoms. Methods Patients who underwent ureteral stent placement after ureterolithotripsy (total 51), were randomized into three groups Group I Tamsulosin 0.4 mg. once per day(17 patients), Group II Oxybutinin 5 mg. once per day (17 patients), Group III Tamsulosin+ oxybutynin once per day (17 patients). All the groups received the drugs for three weeks and completed a Spanish validated Ureteral Stent Symptom Questionnaire (USSQ) at day 7 and 21. Results Repeated measures ANOVA showed mean urinary symptom index score was 22.3 vs. 15.5 in group three (p<0.001) at day 7 and 21 respectively. The mean work performance index was 6.6 vs 8.1 (p=0.049) favoring tamsulosin group, the mean sexual score was 0.5 vs 1.5 (p=0.03). Among additional problems the mean was 7.2 vs 6.2 (p=0.03). No significant difference was noted among pain and general health index. No side effects were reported. Conclusions Combination therapy with tamsulosin and oxybutynin improved irritative symptoms and work performance as well as sexual matters. Combination therapy should be considered for patients who complained of stent related symptoms.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Sulfonamides / Stents / Lower Urinary Tract Symptoms / Urological Agents / Mandelic Acids Type of study: Controlled clinical trial / Diagnostic study / Observational study / Risk factors Limits: Adult / Female / Humans / Male Language: English Journal: Int. braz. j. urol Journal subject: Urology Year: 2016 Type: Article Affiliation country: Mexico Institution/Affiliation country: Hospital Geral de Mexico/MX

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Sulfonamides / Stents / Lower Urinary Tract Symptoms / Urological Agents / Mandelic Acids Type of study: Controlled clinical trial / Diagnostic study / Observational study / Risk factors Limits: Adult / Female / Humans / Male Language: English Journal: Int. braz. j. urol Journal subject: Urology Year: 2016 Type: Article Affiliation country: Mexico Institution/Affiliation country: Hospital Geral de Mexico/MX